INBRX-109
inhibrx
['sarcoma']
 thrilled to present to the world today --&gt;a new drug for patients with #chondrosarcoma hot off the press for #asco23 --&gt;preclinical characterization and phase 1 trial results of inbrx-109, a third-generation, recombinant, humanized, death receptor 5 agonist 
Chief, Early-Phase Drug Development|@SarahCannonDocs
#Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.